Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 USD | +3.34% | -10.05% | -61.32% |
04-26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
04-12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Sales 2024 * | 282M 22.54B | Sales 2025 * | 386M 30.91B | Capitalization | 354M 28.37B |
---|---|---|---|---|---|
Net income 2024 * | -185M -14.81B | Net income 2025 * | -89M -7.12B | EV / Sales 2024 * | 2.36 x |
Net Debt 2024 * | 309M 24.72B | Net Debt 2025 * | 230M 18.38B | EV / Sales 2025 * | 1.51 x |
P/E ratio 2024 * |
-1.64
x | P/E ratio 2025 * |
-3.22
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.53% |
Latest transcript on Revance Therapeutics, Inc.
1 day | +3.34% | ||
1 week | -10.05% | ||
Current month | -30.89% | ||
1 month | -27.66% | ||
3 months | -42.95% | ||
6 months | -57.18% | ||
Current year | -61.32% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 04/09/17 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 04/11/18 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 28/02/11 |
Mark Foley
CEO | Chief Executive Officer | 58 | 04/09/17 |
Jill Beraud
BRD | Director/Board Member | 63 | 03/06/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.4 | +3.34% | 2,280,332 |
25/04/24 | 3.29 | -7.84% | 2,646,582 |
24/04/24 | 3.57 | -2.46% | 1,789,023 |
23/04/24 | 3.66 | +0.55% | 1,588,720 |
22/04/24 | 3.64 | -3.70% | 1,812,785 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.32% | 354M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- RVNC Stock